Pharmaceuticals News and Research

RSS

Thermo Fisher Scientific first quarter revenues increase 14% to record $3.10 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2012.

From Thermo Fisher Scientific Inc. 25 Apr 2012

S-equol effective in reducing menopausal hot flashes, muscle and joint pain among U.S. women

A dose of 10 milligrams (mg) daily of S-equol delivered via a newly developed fermented soy germ-based nutritional supplement is as effective as a standard dose of soy isoflavones at reducing hot flash frequency significantly and is even more effective for relieving muscle and joint pain, according to a peer-reviewed study in US postmenopausal women published in the June Journal of Women's Health, available now as a Fast Track article online ahead of print.

25 Apr 2012

Amgen announces agreement to acquire Mustafa Nevzat

Amgen, the world's largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which Amgen will acquire 95.6 percent of shares in MN, a privately held Turkish pharmaceutical company, for an amount that values MN at US $700 million.

25 Apr 2012

Louisiana Tech professor receives NSF CAREER grant

Dr. Niel Crews, assistant professor of mechanical engineering at Louisiana Tech University and a member of Tech's Institute for Micromanufacturing, has been awarded an Early Career Development grant by the National Science Foundation (NSF) for his proposal, "Thermal Gradient Microflow Calorimetry using Anisotropic Temperature Sensors."

25 Apr 2012

Study finds negative health effects of anti-depressants

Commonly prescribed anti-depressants appear to be doing patients more harm than good, say researchers who have published a paper examining the impact of the medications on the entire body.

25 Apr 2012

Crucell, ARTES enter research collaboration to develop two vaccines

ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharmaceutical company Crucell. Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.

25 Apr 2012

Codexis receives FDA approval for sitagliptin manufacturing process

Codexis, Inc., a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.

25 Apr 2012

Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg.

25 Apr 2012

Gabapentin drug helps people to quit cannabis

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.

24 Apr 2012

Scientists identify new way to deliver long-lasting pain relief

Scientists at the University of North Carolina at Chapel Hill have identified a new way to deliver long-lasting pain relief through an ancient medical practice.

24 Apr 2012

New report presents FDA's focus on global cooperation for product safety

The U.S. Food and Drug Administration Commissioner Margaret A. Hamburg, M.D. today released the agency's "Global Engagement Report," detailing the many activities and strategies FDA is using to transform from a domestic to a global public health agency. The report describes the steps the agency is taking to ensure that imported food, drugs, medical devices, and other regulated products meet the same rigorous standards for safety and quality as those manufactured domestically.

24 Apr 2012

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy.

24 Apr 2012

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

Champ Medics to market ETView's VivaSight airway management platform in Taiwan

ETView Medical, Ltd. announced today that it has entered into a distribution agreement with Champ Medics Co., Ltd..

23 Apr 2012

FDA extends review period for linaclotide NDA to treat constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

23 Apr 2012

APCR honors PAREXEL COO with Special Recognition Award

PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced that its Chief Operating Officer (COO), Mark A. Goldberg, M.D., was honored by the Academy of Physicians in Clinical Research.

From Parexel 23 Apr 2012

MicuRx completes MRX-I Phase 1 trial on MRSA and VRE infection

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.

23 Apr 2012

HBO2 therapy can reduce neuropathic pain

Chronic pain affects about 76 million people in the U.S. and carries an economic burden of nearly $100 billion annually. The most frequently used medications, narcotic and non-narcotic analgesic drugs (e.g., morphine, ibuprofen, etc.), do not provide complete or sustained relief of chronic pain. Scientists are currently seeking alternative solutions for chronic pain management.

23 Apr 2012

FDA warns about contaminated ultrasound gel

The U.S. Food and Drug Administration (FDA) has issued warnings for doctors, hospitals and clinics regarding contaminated ultrasound gel produced by a New Jersey company that infected 16 cardiac patients and could pose serious risks to pregnant women and others who undergo ultrasound imaging and treatment.

22 Apr 2012

Acetylon receives U.S. patent for ACY-1215 to treat multiple myeloma

Acetylon Pharmaceuticals Inc. today announced that it has been granted U.S. Patent 8,148,526 by the United States Patent and Trademark Office (USPTO). This patent contains fundamental composition of matter claims covering the Company's selective HDAC6 inhibitor, ACY-1215, which is currently being investigated in human clinical trials for the treatment of multiple myeloma.

21 Apr 2012